

The Medicines Patent Pool Governance Board Meeting 25

October 14-15, 2019
Geneva, Switzerland

Attendees

Governance Board Members:

Dr Marie-Paule Kieny, Dr Charles Clift, Dr Claudia Chamas, Dr Patrizia Carlevaro and Mr. Mohammed Barry.

Non-voting members:

Mr. Maximiliano Santa Cruz, Dr Mariângela Batista Galvão Simão - WHO observer*, Phillipe Duneton – Unitaid Executive Team*, Jan Akko Eleveld – Unitaid Project Team*, Robert Matiru – Unitaid Executive Team* and Ademola Osigbesan – Unitaid Quality Division*

The Medicines Patent Pool Foundation Staff Members:

Charles Gore – Executive Director, Karine Belondrade – Head of Strategy, Operations and Resource Mobilisation, Vincent Chauvin – CFO, Head of Human Resources, Sandra Nobre – Head of Business Development, Chan Park – General Counsel, Sophie Thievenaz – Head of Communications a.i., Liudmyla Maistat – Policy and Advocacy Manager, Vivian Ntinyari – Grants and Operations Manager (rapporteur), Hannah Barron Moak – Business Development Manager*, Nicola Loffredi – Business Development Manager*, Maica Trabanco – Associate Counsel* and Andrew Goldman – Associate Counsel*.

**These individuals attended part of the Board meeting only*

Summary of Decisions¹

The Governance Board of the Medicines Patent Pool:

- a. Approves a formal review of the functioning of the Board and its sub-committees to ensure effective governance of MPP.
- b. Approves the agenda of the Governance Board Meeting #25.
- c. Approves and adopts the minutes of Governance Board meeting #24 held on April 8 - 9, 2019.
- d. Approves the 2019 financial semi-annual report and the cash disbursement request for July to December 2019 expenditures and 4 months rolling advance into 2020.
- e. Approves the extension of Dr Anban Pillay's mandate for one-year until December 2020 and requests that the Secretariat continues its efforts to identify a suitable replacement. Consulting with WHO and reviewing the attendance records of the World Health Assembly in past years was suggested.
- f. Approves the call for applications to fill the vacant Board seat.

¹ Governance Board meeting #25 did not have a quorum and decisions were approved electronically after the meeting.

- g. Requests the Secretariat to move forward with the feasibility study to explore MPP's potential role in biologics and presents available findings at the April 2020 Board meeting.
- h. Requests the Secretariat to carry out an in-depth assessment of the existing gaps in quality assurance if any - through discussion with WHO, consulting with generic manufacturers and exploring traceability options – and present to the Board in April 2020 potential options for closing those gaps.